Intuor Technologies, Inc.   Report issue

For profit Phase 4
Founded: Tucson AZ United States (2013)
Status: No NME R&D (2013)

Organization Overview

First Clinical Trial
2013
NCT03025945
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Intuor Technologies, Inc.

Active Ingredients

Drugs in Phase 4 Trials (1)

latanoprost (xalatan) (1 trial)

Drugs in Other Trials (2)

nepafenac (nevanac) (1 trial)

sodium chloride (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Glaucoma (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 2
  • # of Trial APIs: 3